OmniAb announced a global collaboration and license agreement with Eli Lilly for an ion channel program, including an upfront payment and up to $370 million in milestone payments. This deal significantly boosts OmniAb's financial outlook and validates its technology, leading to a substantial premarket stock rally.
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly (LLY) for an ion channel program. This is a significant positive catalyst for OmniAb, as it includes an upfront payment, up to $370 million in milestone payments, and tiered royalties, validating its discovery technology. The company also raised its 2026 cash outlook, directly attributable to recent licensing activity. For traders, this presents a short-term opportunity in OABI due to the immediate stock rally, but also a risk of pullbacks given the 'overbought' technical indicators. Long-term, it strengthens OmniAb's financial position and market credibility, while for Eli Lilly, it's a strategic move to leverage OmniAb's expertise in a new program with relatively low initial financial commitment.